Navigation Links
Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Date:4/20/2012

EAST BRUNSWICK, N.J., April 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's first quarter financial results will be released prior to the open of the market on Wednesday, May 9, 2012.
Savient executive management will host a conference call beginning at 9:00 a.m. Eastern Time on May 9, 2012, to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 72346185.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  A telephone replay will be available from 12:00 p.m. Eastern Time on May 9, 2012, through 12:00 a.m. Eastern Time on May 16, 2012, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 72346185.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT-IContact: Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellan information@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
2. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
3. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
5. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
6. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
7. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
8. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
9. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
10. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... Israel , Aug. 15, 2017 /PRNewswire/ ... of adult stem cell technologies for neurodegenerative diseases, announced ... 2017. "We are ... Phase 3 trial to investigate NurOwn ® in ... Executive Officer of BrainStorm. "We have agreements with Mass. ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... Hernandez Insurance Agencies, a northern Virginia ... greater DC region, is inaugurating a “New Leash On Life” charity initiative in ... them to be companions for veterans in need. , The Semper K9 organization ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a ... in east Texas, is launching a regional charity effort to provide publicity assistance ... the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations ...
(Date:8/18/2017)... Saint John, IN (PRWEB) , ... August 18, 2017 , ... ... services to communities in northwest Indiana, is campaigning in support of Campagna Academy in ... Formerly referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a ...
(Date:8/18/2017)... ... , ... The Golseth Agency, a Texas based insurance management and financial planning ... charity campaign organized to provide support to Christina Upchurch and her two children after ... her children returned from out of town to find her husband passed away and ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become ... and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
Breaking Medicine News(10 mins):